The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Low LDL cholesterol,PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
Open accessAbstract
Objective To test the hypothesis that low density lipoprotein (LDL) cholesterol due to genetic variation in the genes responsible for LDL cholesterol metabolism and biosynthesis(PCSK9 and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), respectively) is associated with a high risk of Alzheimer’s disease, vascular dementia, any dementia, and Parkinson’s disease in the general population. Design Mendelian randomisation study. Setting Copenhagen General Population Study and Copenhagen City Heart Study. Participants 111 194 individuals from the Danish general population. Main outcome measures Risk of Alzheimer’s disease, vascular dementia, all dementia, and Parkinson’s disease. Results In observational analyses, the multifactorially adjusted hazard ratio for Parkinson’s disease in participants with an LDL cholesterol level <1.8 mmol/L versus ≥4.0 mmol/L was 1.70 (95% confidence interval 1.03 to 2.79), whereas the corresponding hazard ratios for Alzheimer’s disease, vascular dementia, or any dementia did not differ from 1.0. PCSK9 and HMGCR variants combined were associated with a 9.3% lower LDL cholesterol level. In genetic, causal analyses adjusted for age, sex, and year of birth, the risk ratios for a lifelong 1 mmol/L lower LDL cholesterol level were 0.57 (0.27 to 1.17) for Alzheimer’s disease, 0.81 (0.34 to 1.89) for vascular dementia, 0.66 (0.34 to 1.26) for any dementia, and 1.02 (0.26 to 4.00) for Parkinson’s disease. Summary level data from the International Genomics of Alzheimer’s Project using Egger Mendelian randomisation analysis gave a risk ratio for Alzheimer’s disease of 0.24 (0.02 to 2.79) for 26 PCSK9 and HMGCR variants, and of 0.64 (0.52 to 0.79) for 380 variants of LDL cholesterol level lowering. Conclusion Low LDL cholesterol levels due to PCSK9 and HMGCR variants had no causal effect on high risk of Alzheimer’s disease, vascular dementia, any dementia, or Parkinson’s disease; however, low LDL cholesterol levels may have a causal effect in reducing the risk of Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PCSK9 loss of function mutations carriers are at neutral risk of developing AD (86, 100, 101)”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there is no consensus for an association between PCSK9 genetic variants and AD”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some genetic studies suggest that PCSK9 loss-of-function variants confer protection against AD, whereas others show no association.”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Mendelian randomization studies—which test whether genetically determined changes in PCSK9 influence disease susceptibility—have generally suggested that PCSK9 is unlikely to be a causal determinant of AD [23].”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an analysis based on the Mendelian randomization approach in the Danish population enrolled in two different prospective studies evidenced no causal effects of PCSK9 genetic variants on the risk of AD and also of other forms of dementia and Parkinson’s disease [123].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [123]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“By contrast, genetic analyses—including GWAS and Mendelian randomization—generally failed to identify a causal link between PCSK9 and disease risk [23,25,26].”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“However, the relationship between PCSK9 and AD is still largely unknown, as genetic studies have given opposite indications of the association between PCSK9 variants and AD predisposition [8,9,10].”
From PCSK9 affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer’s disease (2022) · cites this paper as [9]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, preclinical work alternately supports pro-amyloidogenic effects, negligible impact, or even context-dependent neuroprotection.”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“Examples of exposure sets where multivariable Mendelian randomization has been used include lipid fractions (such as high-density lipoprotein cholesterol, LDL-cholesterol, and triglycerides) 82 , and body composition measures (such as fat mass and fat-free mass) 83 .”
From Guidelines for performing Mendelian randomization investigations (2020) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Flagged first, then by citations
Research works printed but not linked: 2
- [26]Nordestgaard BG, Palmer TM, Benn M, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med 2012; 9: e1001212 10.1371/journal.pmed.1001212 pmid:22563304. 22563304 PMC3341326 · DOI
- [35]Instrumental variables and GMM: estimation and testing. Stata J 2003; 3: 1- 33.
Cited by
Sorted by citations
Guidelines for performing Mendelian randomization investigations
Burgess, S., Smith, G. D., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.1 · Cited by 1,828
Guidelines for performing Mendelian randomization investigations
Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.2 · Cited by 1,273
Guidelines for performing Mendelian randomization investigations: update for summer 2023
Burgess, S., Smith, G. D., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Kutalik, Z., Holmes, M. V., Minelli, C., et al. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.3 · Cited by 747
Zuber, V., Grinberg, N. F., Gill, D., Manipur, I., Slob, E. A. W., Patel, A., Wallace, C., & Burgess, S. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.04.001 · Cited by 532
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis
Larsson, S. C., Traylor, M., Malik, R., Dichgans, M., Burgess, S., & Markus, H. S. (2017) · BMJ · doi:10.1136/bmj.j5375 · Cited by 382
Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases
Song, Y., Liu, J., Zhao, K. Z., Gao, L., & Zhao, J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.001 · Cited by 334
Burgess, S., Foley, C. N., & Zuber, V. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021731 · Cited by 291
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
The Role of Lipids in Parkinson’s Disease
Xicoy, H., Wieringa, B., & Martens, G. J. M. (2019) · Cells · doi:10.3390/cells8010027 · Cited by 262
Roeters van Lennep, J. E., Tokgözoğlu, L. S., Badimon, L., Dumanski, S. M., Gulati, M., Hess, C. N., Holven, K. B., Kavousi, M., Kayıkçıoğlu, M., Lutgens, E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad472 · Cited by 229
Self-citationOlmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab208 · Cited by 197
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates
Rees, J. M. B., Wood, A., Dudbridge, F., & Burgess, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222362 · Cited by 177
Cardiovascular Disease and Alzheimer's Disease: The Heart–Brain Axis
Saeed, A., López, O. L., Cohen, A. D., & Reís, S. E. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030780 · Cited by 181
Lipid lowering and Alzheimer disease risk: A mendelian randomization study
Williams, D. M., Finan, C., Schmidt, A. F., Burgess, S., & Hingorani, A. D. (2020) · Annals of Neurology · doi:10.1002/ana.25642 · Cited by 157
Molecular mechanisms for ABCA1-mediated cholesterol efflux
Chen, L., Zhao, Z.-W., Zeng, P.-H., Zhou, Y.-J., & Yin, W.-J. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2042777 · Cited by 134
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 286
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Benn, M., & Nordestgaard, B. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy045 · Cited by 133
Self-citationMedical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study
DeBoever, C., Tanigawa, Y., Lindholm, M. E., McInnes, G., Lavertu, A., Ingelsson, E., Chang, C. C., Ashley, E. A., Bustamante, C. D., Daly, M. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03910-9 · Cited by 125
The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease
García‐Sanz, P., Aerts, J. M. F. G., & Moratalla, R. (2020) · Movement Disorders · doi:10.1002/mds.28396 · Cited by 126
Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease
Nordestgaard, L. T., Christoffersen, M., & Frikke‐Schmidt, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179777 · Cited by 128
PCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 108
Apaijai, N., Moisescu, D. M., Palee, S., McSweeney, C. M., Saiyasit, N., Maneechote, C., Boonnag, C., Chattipakorn, N., & Chattipakorn, S. C. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010838 · Cited by 90
O’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
Low levels of low-density lipoprotein cholesterol and cognitive decline
Hua, R., Ma, Y., Li, C., Zhong, B., & Xie, W. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.02.018 · Cited by 88
Using human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 90
Winchester, L. M., Powell, J. F., Lovestone, S., & Nevado‐Holgado, A. J. (2018) · Genome Medicine · doi:10.1186/s13073-018-0556-z · Cited by 85
Zhang, X., Hu, W., Wang, Y., Wang, W., Liao, H., Zhang, X., Kiburg, K., Shang, X., Bulloch, G., Huang, Y., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02449-3 · Cited by 83
Thomassen, J. Q., Tolstrup, J. S., Benn, M., & Frikke‐Schmidt, R. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000347 · Cited by 81
Self-citationFu, X., Wang, Y., He, X., Li, H., Liu, H., & Zhang, X. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01284-w · Cited by 75
Carroll, C., & Wyse, R. K. H. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171203 · Cited by 73
Low-Density Lipoprotein Cholesterol and Alzheimer's Disease: A Systematic Review and Meta-Analysis
Zhou, Z., Liang, Y., Zhang, X., Xu, J., Lin, J., Zhang, R., Kang, K., Liu, C., Zhao, C., & Zhao, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00005 · Cited by 73
Cheng, L., Zhuang, H., Ju, H., Yang, S., Han, J., Tan, R., & Hu, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00094 · Cited by 66
Familial Hypercholesterolemia and Risk of Peripheral Arterial Disease and Chronic Kidney Disease
Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01058 · Cited by 65
Self-citationAdorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00120 · Cited by 67
Cesaro, A., Bianconi, V., Gragnano, F., Moscarella, E., Fimiani, F., Monda, E., Scudiero, O., Limongelli, G., Pirro, M., & Calabrò, P. (2020) · BioFactors · doi:10.1002/biof.1619 · Cited by 68
Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies
Ference, B. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.007 · Cited by 65
Nordestgaard, L. T., Christoffersen, M., Lauridsen, B. K., Afzal, S., Nordestgaard, B. G., Frikke‐Schmidt, R., & Tybjærg‐Hansen, A. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3728 · Cited by 64
Rosenson, R. S., Hegele, R. A., & Köenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 61
Benn, M., Marott, S. C. W., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab368 · Cited by 64
Self-citationRao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., & Ingelsson, E. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002162 · Cited by 60
Hypercholesterolaemia – practical information for non-specialists
Soran, H., Adam, S., Mohamad, J. B., Ho, J. H., Schofield, J. D., Kwok, S., Siahmansur, T. J., Liu, Y., Syed, A. A., Dhage, S. S., et al. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.72238 · Cited by 59
ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants
Kuo, C.-L., Pilling, L. C., Atkins, J. L., Kuchel, G. A., & Melzer, D. (2020) · Aging · doi:10.18632/aging.103405 · Cited by 55
Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality
Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.517 · Cited by 51
Self-citationFeng, Z., Li, X., Tong, W. K., He, Q., Zhu, X. L., Xiang, X., & Tang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894685 · Cited by 53
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Mannarino, M. R., Sahebkar, A., Bianconi, V., Șerban, M.-C., Banach, M., & Pirro, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.012 · Cited by 48
Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals
Benn, M., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2020) · Diabetologia · doi:10.1007/s00125-020-05124-5 · Cited by 46
Self-citationBenn, M., Emanuelsson, F., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2021) · Diabetologia · doi:10.1007/s00125-021-05436-0 · Cited by 41
Self-citationRisky behaviors and Parkinson disease
Grover, S., Del, G. M. F., Kasten, M., Klein, C., Lill, C. M., & König, I. R. (2019) · Neurology · doi:10.1212/wnl.0000000000008245 · Cited by 48
Mefford, M. T., Rosenson, R. S., Cushman, M., Farkouh, M. E., McClure, L. A., Wadley, V. G., Irvin, M. R., Bittner, V., Safford, M. M., Somaratne, R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029785 · Cited by 44
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
Wang, Q., Wang, Y., Lehto, K., Pedersen, N. L., Williams, D. M., & Hägg, S. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.007 · Cited by 42
Papotti, B., Adorni, M. P., Marchi, C., Zimetti, F., Ronda, N., Panighel, G., Lupo, M. G., Vilella, A., Giuliani, D., Ferri, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012192 · Cited by 41
Yeung, C. H. C., Yeung, S. L. A., Kwok, M. K., Zhao, J. V., & Schooling, C. M. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-01015-2 · Cited by 43
Hu, S., Lin, Z., Hu, M., Tan, J., Guo, T., Huang, X., & Hua, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04580-y · Cited by 40
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
Tan, J., Hu, M., Yang, Y., & Yang, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.798334 · Cited by 39
Zhang, X., Geng, T., Li, N., Wu, L., Wang, Y., Zheng, D., Guo, B., & Wang, B. (2022) · Nutrients · doi:10.3390/nu15010069 · Cited by 35
Thau, H., Neuber, S., Emmert, M. Y., & Nazari‐Shafti, T. Z. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00353-w · Cited by 42
PCSK9 and the nervous system: a no-brainer?
Jaafar, A. K., Techer, R., Chemello, K., Lambert, G., & Bourane, S. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100426 · Cited by 35
“mutations carriers are at neutral risk of developing AD (86, 100, 101).”
BackgroundRe-thinking Alzheimer's disease therapeutic targets using gene-based tests
Kwok, M. K., Lin, S. L., & Schooling, C. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.001 · Cited by 35
ApoB, small-dense LDL-C, Lp(a), LpPLA 2 activity, and cognitive change
Pokharel, Y., Mouhanna, F., Nambi, V., Virani, S. S., Hoogeveen, R. C., Alonso, Á., HEISS, G. M., Coresh, J., Mosley, T. H., Gottesman, R. F., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007574 · Cited by 35
Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
Schlüter, K., Wolf, A., & Schreckenberg, R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.598649 · Cited by 35
The potential role of cholesterol in Parkinson’s disease neuropathology: perpetrator or victim
Alrouji, M., Al-Kuraishy, H. M., Al-Mahammadawy, A.-K. A. A., Al-Gareeb, A. I., Saad, . M., & Batiha, G. E. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06926-2 · Cited by 32
REMOVED: Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease
Ozkızılcık, A., Sharma, A., Lafuente, J. V., Muresanu, D. F., Nozari, A., Tian, Z. R., Mössler, H., & Sharma, H. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.014 · Cited by 29
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 31
Xie, Y.-Y., Zhao, L., Gao, L., Xu, R., Gao, Y., Dou, K., Guo, Y., & He, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01729-4 · Cited by 28
Jiang, Z., Xu, X., Gu, X., Ou, R., Luo, X., Shang, H., & Song, W. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00597 · Cited by 27
Loss-of-function PCSK9 mutations are not associated with Alzheimer disease
Paquette, M., Saavedra, Y. G. L., Poirier, J., Théroux, L., Dea, D., Baass, A., & Dufour, R. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718764330 · Cited by 26
Causal cardiovascular risk factors for dementia: insights from observational and genetic studies
Kjeldsen, E. W., & Frikke‐Schmidt, R. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae235 · Cited by 29
Ren, Q. W., Teng, T. K., Tse, Y.-K., Tsang, C. T., Yu, S.-Y., Wu, M., Li, X., Hung, D., Tse, H., Lam, C. S. P., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.101006 · Cited by 27
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Goodman, S. G., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae025 · Cited by 27
Tada, H., Usui, S., Sakata, K., Takamura, M., & Kawashiri, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17040 · Cited by 26
Liu, G., Shi, M., Mosley, J. D., Weng, C., Zhang, Y., Lee, M. T. M., Jarvik, G. P., Hakonarson, H. H., Namjou‐Khales, B., Abou‐Sleiman, P. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.12820 · Cited by 24
Colín‐Castelán, D., & Zaina, S. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09486-z · Cited by 19
Nounu, A., Greenhough, A., Heesom, K. J., Richmond, R. C., Zheng, J., Weinstein, S. J., Albanes, D., Baron, J. A., Hopper, J. L., Figueiredo, J. C., et al. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1176 · Cited by 23
Raccah, B. H., Yanovsky, A., Treves, N., Rotshild, V., Renoux, C., Danenberg, H. D., Eliaz, R., & Matok, I. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.04.025 · Cited by 21
Perrot, N., Pelletier, W., Bourgault, J., Couture, C., Li, Z., Mitchell, P. L., Ghodsian, N., Bossé, Y., Thériault, S., Mathieu, P., et al. (2021) · Aging Cell · doi:10.1111/acel.13497 · Cited by 20
Pan, X., Luo, Y., Zhao, D., & Zhang, L. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03375-y · Cited by 22
Huang, S.-Y., Yang, Y.-X., Zhang, Y.-R., Kuo, K., Li, H.-Q., Shen, X.-N., Chen, S.-D., Chen, K.-L., Dong, Q., Tan, L., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220050 · Cited by 21
Williams, D. M., Bandrés‐Ciga, S., Heilbron, K., Hinds, D. A., & Noyce, A. J. (2020) · Annals of Neurology · doi:10.1002/ana.25880 · Cited by 19
Hassen, C. B., Machado‐Fragua, M. D., Landré, B., Fayossé, A., Dumurgier, J., Mika Kivimaki, B., Sabia, S., & Singh‐Manoux, A. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13140 · Cited by 19
Exploring Risk and Protective Factors in Parkinson’s Disease
Beheshti, I. (2025) · Cells · doi:10.3390/cells14100710 · Cited by 18
Lee, Y., Kim, M. Y., Han, K., Kim, B., Park, J., Kim, G., Hur, K. Y., Kim, J. H., & Jin, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-24153-1 · Cited by 18
Guo, X., Yu, J., Wang, R., Peng, N., & Li, R. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01424-9 · Cited by 21
Sagris, D., Ntaios, G., Georgiopoulos, G. A., Kakaletsis, N., Elisaf, M., Katsiki, N., Korompoki, E., Kypreos, K. E., Boutari, C., Bilianou, H. I., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493020971970 · Cited by 18
Pierzchlińska, A., Droździk, M., & Białecka, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212198 · Cited by 18
Cacabelos, R. (2018) · Future Neurology · doi:10.2217/fnl-2017-0038 · Cited by 18
Long-term levels of LDL-C and cognitive function: the CARDIA study
Mefford, M. T., Chen, L., Lewis, C. E., Muntner, P., Sidney, S., Launer, L. J., Monda, K. L., Ruzza, A., Kassahun, H., Rosenson, R. S., et al. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617721000059 · Cited by 15
Blood Cholesterol Decreases as Parkinson’s Disease Develops and Progresses
Wang, K., Luo, Z., Li, C., Huang, X., Shiroma, E. J., Simonsick, E. M., & Chen, H. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212670 · Cited by 17
Chen, Y., Liu, Q., Liu, J., Wei, P., Li, B., Wang, N., Liu, Z., & Wang, Z. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08670-2 · Cited by 17
Genetic evidence for the liver-brain axis: lipid metabolism and neurodegenerative disease risk
Wang, Z., Yin, Z., Sun, G., Zhang, D., & Zhang, J. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02455-3 · Cited by 16
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
Ruiz, S., Ivern, C., Badosa, N., Farré, N., Marco, E., Bruguera, J., Cladellas, M., Enjuanes, C., Cainzos‐Achirica, M., Martí‐Almor, J., et al. (2019) · European Journal of Cardiovascular Nursing · doi:10.1177/1474515119831511 · Cited by 17
Serum lipids and the pathogenesis of Parkinson's disease: A systematic review and meta‐analysis
Lu, Y., Jin, X., & Zhao, P. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13865 · Cited by 15
Testa, G., Giannelli, S., Staurenghi, E., Cecci, R., Floro, L., Gamba, P., Sottero, B., & Leonarduzzi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413637 · Cited by 14
“In addition, an analysis based on the Mendelian randomization approach in the Danish population enrolled in two different prospective studies evidenced no causal effects of PCSK9 genetic variants on the risk of AD and also of other forms of dementia and Parkinson’s disease [123].”
Guo, X., Yang, Y., Zhou, R., Tian, G., Shan, C., Liu, J., & Li, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02924-w · Cited by 15
Metadata
- Authors
- Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Benn, Marianne
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2017-04-24
- Volume
- 357
- Pages
- j1648
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- PMC
- PMC5421439
- OpenAlex
- W2607529696
- Cited by
- 178
- References
- 49
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 22 · 2023: 14 · 2022: 21 · 2021: 23 · 2020: 22 · 2019: 18 · 2018: 22 · 2017: 10
- FWCI
- 20.18
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-06-29)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMJ (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Gentofte Hospital
- Herlev Hospital
- Lundbeckfonden (R126-2012-12556, R211-2015-3977)
- Danmarks Frie Forskningsfond
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- low LDL cholesterol, PCSK9, HMGCR, Alzheimer's disease, Parkinson's disease, vascular dementia, dementia, LDL cholesterol metabolism, genetic variants
- MeSH terms
- Proprotein Convertase 9, Adult, Aged, Alzheimer Disease, Denmark, Female, Follow-Up Studies, Genotype, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Parkinson Disease, Prospective Studies, Genetic Variation, Biomarkers, Proportional Hazards Models, Genetic Predisposition to Disease, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
